A simplified version of a treatment pioneered in India to treat limbal stem cell deficiency (LSCD) has demonstrated comparable efficacy to its predecessor but at just 10% of the cost, according to a paper published in the British Journal of Ophthalmology.
- Sleek sophisticationJune 18, 2021
- Night-time screen use linked to myopia and poor sleepJune 16, 2021
- DED drops on trackJune 16, 2021
more... editor's choice
Central serous chorioretinopathy (CSCR) is the fourth most common retinal disease¹. But unlike other common retinal diseases, CSCR commonly affects working-age...
As cold weather begins to blanket the Southern Hemisphere, your patients are likely to be thinking about their winter sports activities. While some might...
All practices should have a business plan, which for small or medium-sized practices could be as simple as a one-page document. A larger and more complex...